Science & Evidence

Evidence Before Assertion.

Every decision behind Morning Clarity begins with evidence. We assess how directly research applies to the specific strain and outcome—and communicate both what the findings support and where uncertainty remains.

Human Research

Study the Evidence.

We give relevant human clinical research particular weight, while considering study quality, consistency, and limitations.

Strain-Specific

Exact Strains Matter.

Evidence for one probiotic strain does not automatically apply to another—even within the same species.

Evidence-Led

Clear About Limits.

We distinguish individual study findings from evidence for a finished product and avoid claims broader than the research supports.

The Gut-Brain Connection

How the Gut and Brain Communicate.

The gut-brain axis is a two-way communication network linking the digestive system and the brain. Researchers study how neural, immune, and hormonal signals — and interactions involving the gut microbiome — contribute to this connection. Understanding this relationship is a starting point for exploring the science of gut-brain probiotics.

GO DEEPER Explore the Gut-Brain Connection Learn how the gut and brain communicate through interconnected signaling pathways.

Looking for the science? Explore the Foundational Research

Strain-Specific Science

Why Exact Strains Matter.

Not all probiotics are the same. Even within the same species, strains can differ in their characteristics and the scientific evidence available for each.

That’s why we look at the exact strain, who was studied, how the study was designed, what it measured, and its limitations. Findings for one strain should not automatically be applied to another.

What We Look At

  • Exact Strain
  • Study Design
  • Study Population
  • Measured Outcomes
  • Study Limitations
GO DEEPER Read the Science Behind Probiotic Strains Explore why strain identity matters when evaluating probiotic research.
Human Research on B. longum 1714™

Meet ProbioBrain™.

Among the four strains in Morning Clarity, Bifidobacterium longum 1714™ has been studied in human research exploring stress responses, brain activity, sleep, and selected aspects of well-being.

Findings vary by outcome. Some studies reported differences in selected measures, while others found no significant between-group differences in primary outcomes.

Explore the Research Library

These studies provide strain-level scientific context. They do not establish the efficacy of Morning Clarity as a finished product.

Evidence in Context

What Research Can—and Can't—Tell Us.

Research on an individual probiotic strain helps us understand that strain, but it does not establish the same outcomes for a multi-strain formula. We consider the study design, population, dose, formulation, duration, and measured outcomes when interpreting the evidence.

GO DEEPER Understanding Levels of Scientific Evidence Explore how different types of research contribute to interpreting scientific findings.
Strain-Specific Science

Four Named Strains. Distinct Research Profiles.

Morning Clarity combines four named probiotic strains, each evaluated according to its own research. Evidence for an individual strain does not automatically establish the effects of the finished formula.

Gut-Brain-Related Human Research

Bifidobacterium longum 1714™

Studied in human research involving stress responses, neural activity, and selected sleep- and well-being-related outcomes.

Digestive & Immune Research

Lactobacillus rhamnosus LGG™

A well-studied strain with research on digestive health and selected immune-related outcomes.

Digestive & Immune Research

Bifidobacterium animalis subsp. lactis BB-12™

Studied in relation to digestive function and selected immune-related outcomes.

Supporting Digestive Research

Lactobacillus plantarum UALp-05™

Included in the formula's digestive wellness approach, with attention to evidence for the specific strain.

GO DEEPER Are All Probiotics the Same? Why Strains Matter Learn why probiotic strain identity matters when interpreting scientific research.
Formulation Considerations

A Closer Look at Formulation.

Strain characteristics and formulation ingredients both matter when evaluating a probiotic formula.

STRAIN SELECTION

Histamine and Probiotic Strains

Histamine is not added during probiotic culture production. The manufacturer reports that its Human Health probiotic strains were tested and did not produce histamine under the test conditions.

These findings do not establish that the finished product is histamine-free or suitable for everyone limiting histamine exposure.

FORMULATION INGREDIENT

Understanding Inulin

Inulin is a fermentable dietary fiber commonly described as a prebiotic because certain gut microorganisms can use it.

Its inclusion does not establish a specific prebiotic effect at the amount used. Inulin may cause gas or bloating in some people.

Integrated Strain-to-Capsule Approach

One Connected Group. From Strain to Capsule.

Morning Clarity’s probiotic strains are sourced through Novonesis, and the finished product is manufactured at a Chr. Hansen facility in the United States.

01
STRAIN SOURCING

Probiotic Strains

Morning Clarity’s probiotic strains are sourced through Novonesis.

02
FINISHED PRODUCT

US Manufacturing

The finished product is manufactured at a Chr. Hansen facility in the United States.

How the Companies Are Connected

Novonesis was formed in 2024 when Novozymes and Chr. Hansen combined. This corporate relationship connects strain sourcing and finished-product manufacturing within the same group.

This describes the relationship between strain sourcing and finished-product manufacturing. It does not mean every ingredient comes from one supplier or that every production stage takes place at one facility.

Quality Journey

Quality, From Culture to Capsule.

A considered approach to probiotic sourcing, U.S. manufacturing, and product quality.

  1. 01
    Probiotic Sourcing

    Four Named Strains.

    Each probiotic strain and its declared CFU amount is identified in the formulation.

  2. 02
    U.S. Manufacturing

    Blending, Encapsulation & Packaging.

    Completed at a Chr. Hansen facility in the United States.

  3. 03
    Facility Certification

    NSF/ANSI 455-2 Certified.

    The manufacturing facility holds NSF/ANSI 455-2 certification. This applies to the facility, not the finished product.

  4. 04
    Finished-Product Testing

    Key Quality Checks.

    Finished-product testing covers strain identity, heavy metals, and microbial quality.

  5. 05
    Probiotic Potency

    12.5 Billion CFU Through Best-Before Date.

    Each capsule provides 12.5 billion CFU through the best-before date when stored according to label directions.

Named Strains · U.S. Manufacturing · Quality Testing
Research Library

Explore the Evidence.

Gut-Brain Axis & Strain-Level Research

Research Context

The references below include reviews of the microbiota-gut-brain axis, human clinical trials, mechanistic studies, preclinical research, and reviews involving the probiotic strains used in Morning Clarity. Gut-brain axis reviews describe the broader scientific framework; they do not establish the effects of any specific probiotic strain. Study doses, formulations, durations, and participant populations may differ from the finished product. Laboratory and animal findings do not establish effects in humans, and these studies do not establish the efficacy of Morning Clarity as a finished product.

01 The Gut–Brain Axis

The gut and brain communicate bidirectionally through interconnected neural, endocrine, immune, and metabolic pathways. These reviews summarize the broader scientific framework, including the enteric and central nervous systems and the ways gut microbes may participate in this communication. They provide context for the field rather than evidence for the effects of a particular probiotic strain.

The Microbiota-Gut-Brain Axis REVIEW · COMPREHENSIVE

This comprehensive review examines pathways through which the gut microbiota may interact with brain and gut function, including immune signaling, tryptophan metabolism, the vagus nerve, the enteric nervous system, and microbial metabolites.1

Evidence Note: The review integrates mechanistic, animal, and human research. Evidence strength differs across pathways and outcomes; proposed mechanisms and findings in animal models should not be treated as proof of clinical effects in humans.

Source: Cryan et al. (2019)

Gut/Brain Axis and the Microbiota REVIEW · TRANSLATIONAL EVIDENCE

This review considers bidirectional communication among the central nervous system, enteric nervous system, gastrointestinal tract, and gut microbiota, and examines how preclinical findings compare with evidence available from human studies.2

Evidence Note: The authors describe growing mechanistic evidence but note that high-quality human evidence and causal links between microbiota changes and clinical brain or gut outcomes remain limited. The review supports a research framework, not a universal probiotic effect.

Source: Mayer et al. (2015)

Interactions Between Enteric Microbiota, Central and Enteric Nervous Systems REVIEW · GASTROINTESTINAL CONTEXT

This review focuses on communication between intestinal microbiota, the central nervous system, and the enteric nervous system, including neural, endocrine, immune, and other signaling routes relevant to gastrointestinal function.3

Evidence Note: The review describes evidence from experimental models and clinical associations, including functional gastrointestinal disorders. These findings support continued investigation of the gut-brain relationship but do not establish that a specific probiotic strain will produce a particular clinical outcome.

Source: Carabotti et al. (2015)

02 Bifidobacterium longum 1714™ (ProbioBrain™)

Human and mechanistic research has examined this strain in relation to stress response, brain activity, sleep, and selected measures of well-being. Study designs range from small within-participant research to randomized trials and preclinical investigations.

Stress Response & Cognitive Function HUMAN · WITHIN-PARTICIPANT · N=22

A repeated-measures, placebo-controlled study in 22 healthy men assessed stress responses, cognitive performance, and EEG activity following four weeks of placebo and four weeks of Bifidobacterium longum 1714™.4

Evidence Note: The study reported lower total cortisol output and daily perceived stress during the 1714 phase, along with changes in selected memory-task and EEG measures. The small, all-male sample and sequential design define the scope of these findings.

Source: Allen et al. (2016)

Brain Activity During Social Stress HUMAN · RCT · 4 WEEKS · MEG

A randomized, double-blind, placebo-controlled study examined neural responses during social stress in 40 healthy volunteers taking Bifidobacterium longum 1714™ for four weeks.5

Evidence Note: The trial reported changes in resting-state and stress-related neural oscillations, with some measures associated with subjective vitality. Behavioral responses during the social-stress task were not clearly differentiated between groups.

Source: Wang et al. (2019)

Mood-Related Measures & Well-being HUMAN · RCT · 8 WEEKS

An eight-week randomized, double-blind, placebo-controlled trial in 168 adults aged 18–70 reporting low mood examined mood-related symptoms, sleep, stress, and well-being after Bifidobacterium longum 1714™ supplementation.6

Evidence Note: The primary BDI-II outcome did not differ significantly between groups at Week 4 or Week 8. Selected secondary sleep and well-being measures differed at Week 4, while the vitality measure remained statistically different at Week 8.

Source: Seamans et al. (2026)

Sleep Quality & Well-being HUMAN · RCT · 8 WEEKS

An eight-week randomized, double-blind, placebo-controlled trial involving 89 adults aged 18–45 with impaired sleep quality assessed overall sleep quality, individual sleep measures, well-being, and objective sleep parameters after supplementation with Bifidobacterium longum 1714™.7

Evidence Note: The primary PSQI global score improved in both groups, without a significant between-group difference. Selected sleep-quality and daytime-function measures differed at Week 4, while social functioning and energy/vitality measures differed at Week 8. Objective actigraphy measures did not show significant between-group differences.

Source: Patterson et al. (2024)

Immune Signaling & Tryptophan Metabolism MECHANISTIC · CELL, ANIMAL & BIOMARKERS

Research examined immunoregulatory pathways associated with Bifidobacterium longum 1714™, including strain-associated exopolysaccharide, tryptophan-related metabolites, immune-cell assays, animal models, and human plasma biomarkers.8

Evidence Note: Findings describe potential biological pathways involving immune-cell signaling and tryptophan metabolism. These findings provide mechanistic and biomarker context for further research.

Source: Groeger et al. (2025)

Stress-Related Behavior PRECLINICAL · ANIMAL STUDY

An animal study compared Bifidobacterium longum 1714™ and Bifidobacterium breve 1205 in relation to stress-related behavior and physiological responses in BALB/c mice.9

Evidence Note: The strains showed different patterns across behavioral and physiological measures. These findings provide preclinical context and are not evidence of the same effects in humans.

Source: Savignac et al. (2014)

Maternal Cytokine Response HUMAN · RCT · N=72

A double-blind, randomized, placebo-controlled trial in healthy pregnant women examined oral Bifidobacterium longum 1714™ supplementation from mid-pregnancy until delivery. Cytokine responses were measured in maternal peripheral blood mononuclear cells.10

Evidence Note: The study assessed changes in IL-10 response to selected immune stimuli. No significant between-group differences were observed in the measured maternal immune-cell cytokine responses, providing context for this specific biomarker outcome.

Source: Killeen et al. (2024)

03 Lactobacillus rhamnosus LGG™

Research on LGG™ includes human clinical trials and laboratory studies related to cognitive outcomes, health-related quality of life, immune-cell activity, and intestinal models. Findings vary by study design and outcome.

Cognitive Functioning HUMAN · RCT · 3 MONTHS

A three-month randomized, double-blind, placebo-controlled trial enrolled 200 adults aged 52–75 and examined cognitive performance following Lactobacillus rhamnosus LGG™ supplementation.11

Evidence Note: Greater improvement in total cognition scores was observed among participants meeting predefined cognitive-impairment criteria. The primary analysis included 145 participants; findings describe a specific subgroup rather than all adults.

Source: Sanborn et al. (2020)

Upper Respiratory Symptoms & Health-Related Quality of Life HUMAN · RCT · 12 WEEKS

A 12-week randomized trial in college students evaluated a combined LGG™ and BB-12™ formulation. Outcomes included upper respiratory symptom duration, symptom severity, functional impairment, and health-related quality of life among participants who developed an infection.12

Evidence Note: Among participants who developed upper respiratory infections, the combined probiotic group had a median illness duration two days shorter and a median symptom- severity score 34% lower than placebo. Because both strains were administered together, their individual contributions cannot be isolated.

Source: Smith et al. (2013)

Immune Cell Modulation MECHANISTIC · EX VIVO

A laboratory study examined the effects of LGG™ cells and LGG-derived soluble factors on antigen-presenting cells from healthy blood donors.13

Evidence Note: The tested preparations influenced selected immune receptors, activation markers, and cytokine profiles in laboratory models. These results characterize cellular responses rather than clinical outcomes following oral probiotic supplementation.

Source: Fong et al. (2016)

Intestinal Barrier Function MECHANISTIC · HUMAN INTESTINAL MODELS

Research using human intestinal enteroids and colonoids examined LGG™ in models of epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from people with IBS.14

Evidence Note: LGG™ reduced experimentally induced barrier dysfunction in these intestinal models. The findings provide mechanistic context for intestinal barrier research; they do not quantify clinical outcomes in people taking oral supplements.

Source: Han et al. (2019)

04 Bifidobacterium animalis subsp. lactis BB-12™

Research on BB-12™ includes human studies of gastrointestinal measures, laboratory research on epithelial responses, and reviews of the strain's biological characteristics. Findings vary by formulation, outcome, and study design.

Gut Microbiota, Transit & Metabolites HUMAN · RANDOMIZED CROSSOVER · N=36

A partially blinded, randomized four-period crossover study in 36 healthy adults compared BB-12™ delivered in yogurt smoothies and capsules, measuring gut microbiota, transit time, and fecal short-chain fatty acids.15

Evidence Note: Overall gut microbiota composition, gut transit time, and fecal short-chain fatty acid concentrations did not change significantly across the study cohort. Some bacterial measurements varied by delivery format, including higher relative abundance of B. animalis after BB-12 was delivered in yogurt.

Source: Ba et al. (2021)

Epithelial Antiviral Responses MECHANISTIC · HUMAN INTESTINAL MODEL

A study using human intestinal organoid-derived monolayers examined how BB-12™ and LGG™ influenced epithelial antiviral pathways and influenza A virus replication.16

Evidence Note: Both strains influenced selected antiviral-response pathways in the experimental models. BB-12™ restricted influenza A replication in ileal organoid-derived monolayers, while LGG™ did not show a significant effect on replication. These findings describe a laboratory model, not an outcome in people.

Source: Stepanyan et al. (2026)

Scientific Foundation of BB-12™ REVIEW

A scientific review summarized research on BB-12™, including safety, gastrointestinal survival, and biological characteristics.17

Evidence Note: The review synthesizes existing strain-specific research and proposed biological mechanisms rather than reporting a new controlled clinical trial.

Source: Jungersen et al. (2014)

Health Benefits Research Overview REVIEW

A review summarized preclinical and clinical research on BB-12™ and proposed mechanisms associated with digestive and immune-related outcomes.18

Evidence Note: The review provides a broad overview of the existing BB-12™ literature.

Source: Collins et al. (2025)

05 Lactobacillus plantarum UALp-05™

The references include a human study of a three-strain formulation containing UALp-05™ and broader reviews of Lactobacillus plantarum. They provide formulation-level clinical context and species-level background rather than direct evidence specific to UALp-05™.

Metabolic & Microbiota Response HUMAN · RCT · 10-WEEK INTERVENTION

An 18-week randomized prospective study involving 39 adults with elevated metabolic-syndrome parameters evaluated a three-strain probiotic formulation containing Lactiplantibacillus plantarum UALp-05™, Limosilactobacillus reuteri NCIMB 30242, and Bifidobacterium animalis subsp. lactis B420™. The active intervention ran for 10 weeks.19

Evidence Note: Metabolic-syndrome markers did not change consistently across the full probiotic cohort. Improvements in selected measures were observed in a subset of participants, with response patterns associated with diet and microbiome profiles. Because three strains were combined, the findings cannot be attributed specifically to UALp-05™.

Source: Wastyk et al. (2023)

Gastrointestinal Health & Probiotic Function REVIEW · SPECIES-LEVEL

A narrative review surveyed food and health applications of Lactobacillus plantarum, including probiotic properties and proposed biological mechanisms.20

Evidence Note: This review provides broader species-level background. Its findings are not strain-specific clinical evidence for UALp-05™.

Source: Zare et al. (2024)

Probiotic Properties & Omics Research REVIEW · SPECIES-LEVEL

A review examined probiotic characteristics and omics-based approaches used to investigate the biology of Lactiplantibacillus plantarum.21

Evidence Note: The review provides biological and mechanistic context at the species level. It does not establish a clinical outcome specific to UALp-05™.

Source: Echegaray et al. (2023)

Our Approach

Evidence Is Not All the Same.

We consider the exact strain, study design, population, dose, outcome, and limitations when interpreting research.

  1. Exact Strain
  2. Study Design
  3. Population & Dose
  4. Outcome
  5. Responsible Communication
References

The Research Behind the Evidence.

Published research referenced throughout the Science page is listed below by topic and strain.

01 · The Gut-Brain Axis

  1. Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, Guzzetta KE, Jaggar M, Long-Smith CM, Lyte JM, Martin JA, Molinero-Perez A, Moloney G, Morelli E, Morillas E, O'Connor R, Cruz-Pereira JS, Peterson VL, Rea K, Ritz NL, Sherwin E, Spichak S, Teichman EM, van de Wouw M, Ventura-Silva AP, Wallace-Fitzsimons SE, Hyland N, Clarke G, Dinan TG. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019 Oct 1;99(4):1877-2013. doi: 10.1152/physrev.00018.2018. PMID: 31460832.
  2. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015 Mar 2;125(3):926-938. doi: 10.1172/JCI76304. Epub 2015 Feb 17. PMID: 25689247; PMCID: PMC4362231.
  3. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015 Apr-Jun;28(2):203-209. Erratum in: Ann Gastroenterol. 2016 Apr-Jun;29(2):240. PMID: 25830558; PMCID: PMC4367209.

02 · Bifidobacterium longum 1714™

  1. Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G. Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016 Nov 1;6(11):e939. doi: 10.1038/tp.2016.191. PMID: 27801892; PMCID: PMC5314114.
  2. Wang H, Braun C, Murphy EF, Enck P. Bifidobacterium longum 1714™ Strain Modulates Brain Activity of Healthy Volunteers During Social Stress. Am J Gastroenterol. 2019 Jul;114(7):1152-1162. doi: 10.14309/ajg.0000000000000203. PMID: 30998517; PMCID: PMC6615936.
  3. Seamans KM, Patterson E, Holz C, Groeger D, Junnila J, Collins F, Murphy EF, Sorensen K, Dinan TG. Effects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial. Exp Clin Psychopharmacol. 2026 Apr 30. doi: 10.1037/pha0000839. Epub ahead of print. PMID: 42060410.
  4. Patterson E, Tan HTT, Groeger D, Andrews M, Buckley M, Murphy EF, Groeger JA. Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial. Sci Rep. 2024 Feb 14;14(1):3725. doi: 10.1038/s41598-024-53810-w. PMID: 38355674; PMCID: PMC10866977.
  5. Groeger D, Yao L, Collins F, Larsen IS, Tan HT, Healy S, Ambrogi V, Tykwinska K, Schmidt M, Golletz P, Kiely B, Clarke G, Dinan TG, Murphy EF, O'Mahony L. Complementary immunoregulatory effects of Bifidobacterium longum 1714TM associated exopolysaccharide and tryptophan metabolism. Curr Res Microb Sci. 2025 Sep 28;9:100481. doi: 10.1016/j.crmicr.2025.100481. PMID: 41140527; PMCID: PMC12546897.
  6. Savignac HM, Kiely B, Dinan TG, Cryan JF. Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. Neurogastroenterol Motil. 2014 Nov;26(11):1615-1627. doi: 10.1111/nmo.12427. Epub 2014 Sep 24. PMID: 25251188.
  7. Killeen SL, Mealy G, Brennan K, Cotter PD, Yelverton C, Saldova R, Groeger D, VanSinderen D, Doyle S, McAuliffe FM. Impact of Bifidobacterium longum 1714® on maternal cytokine response in peripheral blood mononuclear cells. Cytokine. 2024 Feb;174:156458. doi: 10.1016/j.cyto.2023.156458. Epub 2023 Dec 9. PMID: 38071842.

03 · Lactobacillus rhamnosus LGG™

  1. Sanborn V, Azcarate-Peril MA, Updegraff J, Manderino L, Gunstad J. Randomized Clinical Trial Examining the Impact of Lactobacillus rhamnosus GG Probiotic Supplementation on Cognitive Functioning in Middle-aged and Older Adults. Neuropsychiatr Dis Treat. 2020 Nov 13;16:2765-2777. doi: 10.2147/NDT.S270035. PMID: 33223831; PMCID: PMC7671471.
  2. Smith TJ, Rigassio-Radler D, Denmark R, Haley T, Touger-Decker R. Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr. 2013;109(11):1999-2007. doi: 10.1017/S0007114512004138.
  3. Fong FLY, Kirjavainen PV, El-Nezami H. Immunomodulation of Lactobacillus rhamnosus GG (LGG)-derived soluble factors on antigen-presenting cells of healthy blood donors. Sci Rep. 2016 Mar 10;6:22845. doi: 10.1038/srep22845. PMID: 26961406; PMCID: PMC4785377.
  4. Han X, Lee A, Huang S, Gao J, Spence JR, Owyang C. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. Gut Microbes. 2019;10(1):59-76. doi: 10.1080/19490976.2018.1479625. Epub 2018 Aug 6. PMID: 30040527; PMCID: PMC6363076.

04 · Bifidobacterium animalis subsp. lactis BB-12™

  1. Ba Z, Lee Y, Meng H, Kris-Etherton PM, Rogers CJ, Lewis ZT, Mills DA, Furumoto EJ, Rolon ML, Fleming JA, Roberts RF. Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp. lactis BB-12 on Fecal Microbiota, Gut Transit Time, and Short-Chain Fatty Acids in Healthy Young Adults. mSphere. 2021 Aug 25;6(4):e00084-21. doi: 10.1128/mSphere.00084-21. Epub 2021 Jul 7. PMID: 34232082; PMCID: PMC8386398.
  2. Stepanyan A, Scarpa M, Bernabè G, Brun P, Pauletto A, Zatta V, Salata C, Del Vecchio C, Scarpa M, Castagliuolo I. Bifidobacterium animalis subsp. lactis BB-12 Primes Epithelial Antiviral Defenses and Restricts Influenza A Virus Replication in Human Intestinal Organoid-Derived Monolayers. Microorganisms. 2026 Mar 27;14(4):751. doi: 10.3390/microorganisms14040751. PMID: 42075148; PMCID: PMC13118500.
  3. Jungersen M, Wind A, Johansen E, Christensen JE, Stuer-Lauridsen B, Eskesen D. The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(®). Microorganisms. 2014 Mar 28;2(2):92-110. doi: 10.3390/microorganisms2020092. PMID: 27682233; PMCID: PMC5029483.
  4. Collins FWJ, Vera-Jiménez NI, Wellejus A. Understanding the probiotic health benefits of Bifidobacterium animalis subsp. lactis, BB-12™. Front Microbiol. 2025 Jul 2;16:1605044. doi: 10.3389/fmicb.2025.1605044. PMID: 40673154; PMCID: PMC12265310.

05 · Lactobacillus plantarum UALp-05™

  1. Wastyk HC, Perelman D, Topf M, Fragiadakis GK, Robinson JL, Sonnenburg JL, Gardner CD, Sonnenburg ED. Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet. Gut Microbes. 2023 Jan-Dec;15(1):2178794. doi: 10.1080/19490976.2023.2178794. PMID: 36803658; PMCID: PMC9980610.
  2. Zare D, Aryaee H, Mirdamadi S, Shirkhan F. The Benefits and Applications of Lactobacillus plantarum in Food and Health: A Narrative Review. Iran J Public Health. 2024 Oct;53(10):2201-2213. doi: 10.18502/ijph.v53i10.16698. PMID: 39544869; PMCID: PMC11557752.
  3. Echegaray N, Yilmaz B, Sharma H, Kumar M, Pateiro M, Ozogul F, Lorenzo JM. A novel approach to Lactiplantibacillus plantarum: From probiotic properties to the omics insights. Microbiol Res. 2023 Mar;268:127289. doi: 10.1016/j.micres.2022.127289. Epub 2022 Dec 22. PMID: 36571922.

Reference Note

Research involving a related strain, species, genus, or multi-strain formulation is identified as such. These studies provide scientific context and do not establish the efficacy of Morning Clarity as a finished product.

Evidence from an exact strain does not necessarily establish that the same outcome will occur with Morning Clarity, as study populations, formulations, doses, durations, and study conditions may differ.

Exact Strain · Transparent Evidence · Responsible Communication

FDA Disclaimer

† These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Educational Notice

Information on this page is provided for general educational purposes only. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional.

Individual responses may vary. If you are pregnant, nursing, taking medication, or managing a medical condition, consult your healthcare professional before using dietary supplements.

Continue Exploring

From Evidence to Everyday Practice.

Our Story

Discover why HEXABIOME was created and the principles behind how we build.

Read Our Story →